Advanced Search

Understanding risk in a biopharmaceutical portfolio

Research and Teaching Output of the MIT Community

Show simple item record

dc.contributor.advisor Fiona Murray and Andrew W. Lo. en_US Wagner, Alice Elizabeth, 1980- en_US
dc.contributor.other Harvard University--MIT Division of Health Sciences and Technology. en_US 2012-01-12T19:30:14Z 2012-01-12T19:30:14Z 2011 en_US 2011 en_US
dc.description Thesis (S.M.)--Harvard-MIT Division of Health Sciences and Technology, 2011. en_US
dc.description Cataloged from PDF version of thesis. "Pages 65-70 contain illegible text. This is the best copy available"--P. after t.p. en_US
dc.description Includes bibliographical references (p. 63-64). en_US
dc.description.abstract Investors have difficulty funding the life sciences because of the high risks involved in research and development and commercialization of new products. Risk in the biopharmaceutical industry is the result of scientific, regulatory and economic uncertainty. The nature of the biopharmaceutical industry introduces many challenges. Each of these challenges incorporates a measure of risk into drug development. The level of understanding of technical success interdependencies has not been fully investigated. These interdependencies (correlations) could lead to an overall greater risk to the company's portfolio than previously expected. A better understanding of the risks that lead to success or failure in drug development might encourage more investment in the life sciences and specifically in the biopharmaceutical industry, and a greater awareness of the correlations between risks and products might lead to more informed decision making on a biopharmaceutical portfolio leading increased productivity. A dataset was collected from Thomson Reuters. The dataset is the oncology portfolio from a biopharmaceutical company, Genentech Inc. Logistic regression was used to determine if any of the defined variables contributed to the success or failure of the oncology products. The chi-square value was 7.738 with the degrees of freedom equal to 5 and with a p-value of 0.17. Therefore, none of the variables significantly contributed to the outcome. More research should be performed in this area in order to better understand the risk in a biopharmaceutical portfolio. en_US
dc.description.statementofresponsibility by Alice Elizabeth Wagner. en_US
dc.format.extent 74 p. en_US
dc.language.iso eng en_US
dc.publisher Massachusetts Institute of Technology en_US
dc.rights M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission. en_US
dc.rights.uri en_US
dc.subject Harvard University--MIT Division of Health Sciences and Technology. en_US
dc.title Understanding risk in a biopharmaceutical portfolio en_US
dc.type Thesis en_US S.M. en_US
dc.contributor.department Harvard University--MIT Division of Health Sciences and Technology. en_US
dc.identifier.oclc 769908949 en_US

Files in this item

Name Size Format Description
769908949-MIT.pdf 5.792Mb PDF Full printable version

This item appears in the following Collection(s)

Show simple item record